Status:
UNKNOWN
Lexiscan(TM) Rb-82 Myocardial Perfusion PET: A Comparison With Dipyridamole Stress
Lead Sponsor:
Cardiovascular Imaging Technologies
Collaborating Sponsors:
Astellas Pharma US, Inc.
Conditions:
Coronary Artery Disease
Eligibility:
All Genders
35-90 years
Phase:
PHASE4
Brief Summary
Lexiscan(TM) has ideal properties for Rb-82 PET imaging and the stress response it invokes may offer multiple advantages for the diagnosis of coronary disease and functional abnormalities. The goal of...
Eligibility Criteria
Inclusion
- BMI \<35
- No intervention or change in management between dipyridamole and Lexiscan(TM) PET
Exclusion
- BMI \>35
- An intervention or change in management between dipyridamole and Lexiscan(TM) PET
Key Trial Info
Start Date :
December 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2012
Estimated Enrollment :
32 Patients enrolled
Trial Details
Trial ID
NCT00808314
Start Date
December 1 2008
End Date
September 1 2012
Last Update
August 2 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Saint Luke's Cardiovascular Consultants
Kansas City, Missouri, United States, 64111